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Dietary flaxseed meal reduces proteinuria and ameliorates
nephropathy in an animal model of type II diabetes mellitus.
Background. Evidence is emerging that varying the type or
source of dietary protein intake can have beneficial effects on
chronic renal disease. Consumption of soybean and soy-based
food products, as the source of plant protein, can retard the de-
velopment and progression of chronic renal disease. We studied
the obese spontaneously hypertensive/NIH-corpulent (SHR/N-
cp) rat, a model of obesity and type II diabetes mellitus that
consistently develops nephropathy resembling diabetic neph-
ropathy. We specifically sought to determine whether chang-
ing the source of protein intake from animal protein, casein,
to plant protein in the form of either soy protein concentrate
or flaxseed protein in the diet has a different impact on renal
function and nephropathy in this model.
Methods. Male obese SHR/N-cp rats were randomly assigned
to one of three diets containing either 20% casein, 20% soy
protein concentrate, or 20% flaxseed meal. Except for the pro-
tein source, all three diets were identical and contained similar
amounts of protein, fat, carbohydrates, minerals, and vitamins.
All animals were maintained on these diets for 6 months. At
the end of the study, blood sampling and 24-hour urine col-
lections were performed for renal functional measurements,
and the kidneys were harvested and examined for histologic
evaluation.
Results. All three groups had similar amounts of food intake
and body weight gain and exhibited fasting hyperglycemia and
hyperinsulinemia. Plasma glucose levels did not differ among
the three groups, but plasma insulin concentration was signifi-
cantly lower in rats fed flaxseed meal than those fed either casein
or soy protein concentrate. Mean plasma creatinine, creatinine
clearance, and urinary urea excretion also did not differ signif-
icantly between the three groups. By contrast, urinary protein
excretion was significantly lower (P < 0.01) in rats fed flaxseed
than in rats fed either casein or soy protein concentrate. Mor-
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phologic analysis of renal structural lesions showed that the per-
centage of abnormal glomeruli with mesangial expansion and
the tubulointerstitial score (an index of severity of tubulointer-
stitial damage) were significantly reduced in rats fed flaxmeal
compared to those fed casein or soy protein concentrate.
Conclusion. We conclude that dietary protein substitution
with flaxseed meal reduces proteinuria and glomerular and
tubulointerstitial lesions in obese SHR/N-cp rats and that
flaxseed meal is more effective than soy protein in reducing
proteinuria and renal histologic abnormalities in this model.
The reduction in proteinuria and renal injury was independent
of the amount of protein intake and glycemic control. Which
dietary component(s) present in flaxseed meal is (are) respon-
sible for the renal protective effect remains to be determined.
There is abundant evidence that varying the amount
of protein in the diet exerts a profound influence on re-
nal function and the course of renal disease [1–5]. High
protein intake has long been known to aggravate renal
injury and accelerates the progression of chronic renal
failure, whereas low protein intake produces the opposite
effects. In addition, there is also evidence that changing
the source or type of dietary protein may have a bene-
ficial effect on renal function and renal disease. This is
supported by nutritional intervention studies in animals
and humans showing that replacement of animal protein
with plant protein in the diet reduces proteinuria and
preserves renal function [6–9]. Evidence is emerging that
consumption of soybean and soy-based food products,
as the source of plant protein, can retard the develop-
ment and progression of chronic renal disease [10–19].
Besides soybean, other plant seeds, particularly flaxseed,
have also received increasing attention for their poten-
tial beneficial role in chronic renal disease. For example,
there are few reports suggesting that dietary flaxseed has
protective effects on the kidney in some animal mod-
els of chronic renal disease [20–22] and in humans with
lupus nephritis [23, 24]. As yet, there are no studies that
have assessed the effect of dietary flaxseed on diabetic
nephropathy.
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The spontaneously hypertensive/NIH-corpulent
(SHR/N-cp) rat is a genetic animal model that exhibits
obesity, type II diabetes mellitus, and mild hypertension
[25–28]. The SHR/N-cp rat is a congenic strain and
was originally derived from an initial mating of a male
obese spontaneously hypertensive (Koletsky) rat which
was heterozygous for the cp gene with a spontaneously
hypertensive rat (SHR) of the Okamoto strain, followed
by multiple cycles of backcrossing of the progeny to the
SHR strain. A minimum of ten backcrosses was carried
out to eliminate the non-cp genes of the Koletsky strain.
Obese homozygotes (cp/cp), unlike their lean littermates,
exhibit marked obesity, glucose intolerance, hyperin-
sulinemia, hyperlipidemia, and mild hypertension.
Obese SHR/N-cp rats also consistently develop marked
proteinuria and renal pathologic lesions characterized by
renal hypertrophy, glomerular mesangial expansion, and
tubulointerstitial lesions, which are features resembling
diabetic nephropathy in humans [29, 30]. The role of
two different dietary types of plant protein, namely
soy protein and flaxseed protein, on nephropathy in
this strain has not been examined. Therefore, we have
studied the obese SHR/N-cp rat to examine the effects
of dietary soy protein isolate and flaxseed meal on
nephropathy in this model. We specifically sought to
determine whether changing the source of protein intake
from animal protein, casein, to either soy protein or
flaxseed protein in the diet has a different impact on the
proteinuria and renal pathologic abnormalities in this
model.
METHODS
Animals
Male obese SHR/N-cp rats were obtained from the
National Institutes of Health at approximately 5 to
6 weeks of age. At this age, obesity is already evident
in SHR/N-corpulent (cp/cp) rats as indicated by higher
body weight than their lean littermates and increased
abdominal girth. The experimental protocol was appro-
ved by the Institutional Animal Care and Use
Committees of the George Washington University,
Washington, D.C., and by the Agricultural Research Ser-
vice, United States Department of Agriculture, Beltsville,
Maryland. All animals were housed simultaneously in
individual stainless steel wire cages with controlled tem-
perature (22◦C to 24◦C) and relative humidity (40% to
50%) and maintained on a reverse 12-hour dark (9:00
a.m. to 9:00 p.m.) and light (9:00 p.m. to 9:00 a.m.) cycle.
Diets and experimental design
All animals were initially provided with Purina rat
chow for 2 weeks and were maintained on this diet until
8 to 10 weeks of age. Food and water were consumed ad
libitum. The rats were then randomly divided into three
groups of 10 rats and fed American Institute of Nutrition
(AIN)-93 diet [31] supplemented with casein, soy protein
concentrate, or flaxseed meal, as the sole source of dietary
protein. Group 1 rats received 20% casein, group 2 rats
received 20% soy protein concentrate, and group 3 rats
received 20% flaxseed meal. With the exception of the
protein source, all three diets were identical and contain
similar amounts of protein, fat, carbohydrates, minerals,
and vitamins. To ensure uniformity of the protein source,
all protein components (casein, soy protein concentrate,
and flaxseed meal) used in this study were obtained from
the same batch. The levels of isoflavones in soy protein
concentrate and lignan content in flaxseed meal were an-
alyzed by Archer Daniels Midland Company, Decatur,
IL. Soy protein concentrate contained 234.9 mg/kg total
isoflavones. Approximately 97% of the isoflavones are in
glucoside form. The ratio of genistein:daidzein:glycitein
(as aglycone equivalents) is 1.3:1:0.3. Flaxseed meal con-
tained 17.0 mg/g secoisolariciresinol diglucoside (SDG).
All diets contained (g/kg) dextrinized cornstarch, 155; su-
crose, 100; corn oil, 40; cellulose, 50; mineral mix (AIN-
93M-MX), 35; vitamin mix (AIN-93-VX), 10; L-cystine,
1.8; choline bitartrate, 2.5; and tert-butylhydroquinone,
0.0008. Amount of cornstarch was adjusted in each diet to
provide 20% of energy from protein. Casein and L-cystine
were purchased from Sigma Chemical Co., St. Louis, MO.
Soy protein concentrate and flaxseed meal were obtained
gratis from Protein Specialties Division, Archer Daniels
Midland. Tert-butylhydroquinone was purchased from
Aldrich Chemical Co., Milwaukee, WI. All other ingre-
dients were obtained from Dyets, Inc., Bethlehem,
PA. All animals were fed the experimental diets for
6 months, and body weight and food intake were mea-
sured biweekly throughout the study. At the end of the
feeding period, animals were placed metabolic cages and
timed-urine collections were made with the rats in the
fasting state. After these collections, rats were weighed
and sacrificed by decapitation under carbon dioxide anes-
thesia. Blood was collected in ethylenediaminetetraacetic
acid (EDTA) and Trasylol (100 KU/L) and plasma was
separated for subsequent biochemical analyses. Immedi-
ately after sacrifice, the abdomen was opened by a midline
incision and the abdominal aorta was perfused with cold
0.9% normal saline using a Cole-Palmer peristaltic pump
set to deliver perfusion solution at a rate of 10 mL/min.
Following perfusion, the kidneys were dissected free of
fat, quickly removed, and weighed. The kidney was tri-
sected coronally and placed in 10% buffered formalin.
Metabolic and renal functional measurements
Plasma concentrations of glucose and plasma and uri-
nary concentrations of urea and creatinine were mea-
sured using Alcyon analyzer and ATAC 8000 (Abbott
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Laboratories, Abbott Park, IL, USA) and kits from
Elan Diagnostics (Smithfield, RI, USA). Plasma in-
sulin was measured by radioimmunoassay using rat in-
sulin as standard. Plasma total protein and urinary
protein excretion was measured by the Lowry method.
Creatinine clearance, an estimate of glomerular filtration
rate (GFR), was determined by standard clearance tech-
niques. Urinary protein excretion was expressed both as
the ratio of urine protein concentration and urine crea-
tinine concentration (mg U protein/mg U creatinine), as
well as the product of urine protein concentration and
urine volume (V) (U protein V in mg/24 hours). Urinary
urea excretion rate (UUNV), an index of protein intake,
was also determined as the product of urine urea concen-
tration and V.
Histology
Glomerular morphology. Coronal sections of the in
situ perfused kidney were embedded in paraffin. The sec-
tions were cut at 3 micra and stained with hematoxylin-
eosin (H&E), periodic acid-Sciff (PAS), and Masson’s
trichrome stains. All cut sections were coded and evalu-
ated blindly by two pathologists without knowledge of
the experimental diets Concordance between the two
pathologists was greater than 95%. The sections were re-
viewed and evaluated separately in the following manner.
Slides were inserted into the micrometer stage of a Nikon
Eclipse Model E600W microscope and scanned in passes
at about 2 mm distance per pass at 200× magnification.
For each specimen, point counting of 50 to 100 consecu-
tive glomeruli within a single section was performed twice
assessing and distinguishing the identity of glomeruli with
normal morphology from those with abnormal lesions,
namely mesangial expansion and glomerular sclerosis.
The total number of abnormal glomeruli and glomeruli
with mesangial expansion and with sclerosis were tabu-
lated and expressed as percentages. Glomerular sclerosis
was defined by the absence of cellular elements in the
tuft, collapse of capillary loops or folding of the glomeru-
lar basement membrane with an accumulation of amor-
phous material, and adhesion of the obsolescent segment
of Bowman’s capsule. The PAS and Masson trichrome
stains were used to assess the extent of mesangial expan-
sion and confirm the presence or absence of glomerular
sclerosis.
Tubulointerstitial morphology. The renal tubules and
surrounding interstitium were evaluated in a semiquan-
titative manner using a grading system with a score of
0 to 4+, which assessed tubulointerstitial damage as fol-
lows: 0 represents normal histology with no pathologic
lesions; 1+ indicates small focal lesion, with very min-
imal tubular atrophy and dilatation, and interstitial in-
flammatory cell infiltration involving less than 25% of
the renal parenchyma and intertstitium; 2+ indicates in-
Table 1. Body weight, food intake, and fasting plasma levels of
glucose and insulin in obese spontaneously
hypertensive/NIH-corpulent (SHR/N-cp) rats fed a diet supplemented
with either casein, soy protein concentrate, or flaxseed meal
Parameter Casein Soy protein Flax meal
Body weight g 558 ± 22 547 ± 26 575 ± 19
Food intake g/day 14.6 ± 1.0 14.7 ± 0.9 12.9 ± 1.0
Serum glucose mmol/L 12.8 ± 2.1 13.3 ± 1.2 12.9 ± 1.6
Serum insulin pmol/L 3485 + 372a 3121 + 296a 2279 + 284b
Values are mean ± SEM of 10 rats.
Values with different superscripts within a row are significantly different at
P < 0.05.
creased tubular dilatation and atrophy, mild inflamma-
tory cell infiltrate without interstitial fibrosis, affecting
25% to 50% of the parenchyma and intertstitium; 3+
indicates increased tubular atrophy and moderate inflam-
matory cell infiltrate with early interstitial fibrosis, involv-
ing 50% to 75% of parenchyma; and 4+ indicates severe
extensive tubulointerstitial changes and fibrosis involv-
ing 75% or more of the parenchyma and interstitium.
The concordance between the two-blinded pathologists
was greater than 95% identical scoring.
Statistical analysis
Results are expressed as mean + standard error of the
mean (SEM). Comparisons between groups were made
using one-way analysis of variance (ANOVA). When an
effect was statistically significant (P < 0.05), mean com-
parisons were made. A Sidak adjusted significance level
was used for the pair-wise comparisons of the means so
that the overall significance level was 0.05. Differences
between means were considered significant when the
P value was less than 0.05.
For analysis of glomerular lesions, the percent of ab-
normal glomeruli was analyzed as a one-factor general
linear model using PROC MIXED with diet as the fac-
tor. Further mean pair-wise comparisons were made with
Sidak adjusted P values. The tubulointerstitial score data
were analyzed by an exact version of the Kruskal-Wallis
nonparametric rank test.
RESULTS
The results of experiments performed in obese SHR/
N-cp rats fed the three different protein diets are sum-
marized in Tables 1 and 2, respectively.
Food intake, weight gain, and metabolic parameters
The animals tolerated the diets and food intake did not
differ significantly between the three diet groups. After
6 months of feeding, all rats gained weight and the mean
final body weight was similar among the three groups.
Obese SHR/N-cp rats consuming either of the three dif-
ferent diets exhibited both hyperglycemia and hyperin-
sulinemia with relatively higher fasting levels of plasma
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Table 2. Renal functional measurements in obese spontaneously
hypertensive/NIH-corpulent (SHR/N-cp) rats fed a diet supplemented
with either casein, soy protein concentrate, or flaxseed meal
Parameter Casein Soy protein Flax meal
Plasma creatinine umol/L 27.5 ± 3.6 24.9 ± 2.9 27.9 ± 2.4
Creatinine clearance 1.44 ± 0.21 1.90 ± 0.35 2.16 ± 0.39
mL/min
Urine urea excretion 216 ± 18 195 ± 15 213 ± 8
mg/24 hours
Urine protein excretion 3.18 ± 0.35a 2.92 ± 0.27a 1.70 ± 0.12b
mg/mg creatinine
mg/24 hours 21.2 ± 2.2a 19.9 ± 2.1a 14.5 ± 1.1b
Values are mean ± SEM of 10 rats.
Values with different superscripts within a row are significantly different at
P < 0.01.
glucose and insulin when compared to lean counterparts,
as has been reported in previous studies in which 10%
casein and 10% lactalbumin were used as the sources of
dietary protein [26, 27]. However, mean fasting levels of
plasma glucose did not differ significantly between the
three groups, regardless of the protein source. Plasma
insulin concentration was slightly lower in rats fed soy
protein concentrate than those fed casein, but the dec-
rease was not statistically significant. In contrast, plasma
insulin was significantly lower in rats fed flaxseed meal
than those fed either casein or soy protein concentrate.
Renal functional measurements
Plasma concentration of creatinine in obese rats fed
casein, which averaged 0.31 ± 0.04 mg/dL, was not signif-
icantly different from those observed in animals fed either
soy protein concentrate (0.28 ± 0.03 mg/dL) or flaxseed
meal (0.32 ± 0.03 mg/dL). However, mean creatinine
clearance was higher in rats fed either soy protein con-
centrate or flaxseed meal than in rats fed casein with the
highest values observed in the animals fed flaxseed meal.
However, these differences between the three groups did
not reach statistical significance. Similarly, mean UUNV
did not differ among the animals fed the three diets. By
contrast, urinary protein excretion, whether expressed as
the ratio of U protein/U creatinine (mg/mg) or as the
product of urine protein concentration and urine volume
(U protein V) (mg/24 hours) was significantly lower (P <
0.01) in rats fed flaxseed than in rats fed either casein or
soy protein concentrate.
Kidney weight and renal histology
Kidney weight of obese rats fed casein averaged
1.91 ± 0.09 g (Table 3). Mean kidney weight of obese rats
fed soy protein concentrate was 1.92 ± 0.09 and nearly
the same as that of rats fed casein. Mean kidney weight
was slightly lower in rats fed flaxseed meal (1.75 ± 0.05)
than in animals fed casein or soy protein concentrate, but
the differences were not stastistically significant.
Table 3. Kidney weight and percentage of glomerular lesions in
obese spontaneously hypertensive/NIH-corpulent (SHR/N-cp) rats
fed a diet supplemented with either casein, soy protein concentrate,
and flaxseed meal
Phenotype Casein Soy protein Flax meal
Kidney weight g
Left 1.83 ± 0.09 1.91 ± 0.08 1.75 ± 0.05
Right 1.92 ± 0.07 1.93 ± 0.07 1.75 ± 0.05
Glomerular lesions %
Total abnormal glomeruli 29.4 ± 3.2a 25.8 ± 3.2a 10.8 ± 3.2b
With mesangial expansion 27.6 ± 3.7a 24.4 ± 1.9a 10.0 ± 2.3b
With glomerular sclerosis 1.80 ± 0.81 1.40 ± 0.79 0.80 ± 0.55
Values are mean ± SEM of 10 rats.
Values with different superscripts within a row are significantly different at
P < 0.01.
On light microscopy, the typical renal lesions of obese
SHR/N-cp rats are shown in Figure 1. The glomeruli of
rats fed casein shows segmental or diffuse mesangial ex-
pansion (as evidenced by increased PAS staining of the
mesangium) with or without increased proliferation of
mesangial cells (Fig. 1A and D). The majority of ab-
normal glomeruli have expanded mesangium but with-
out increased cellularity, whereas only a few glomeruli
show segmental or global sclerosis. The tubulointersti-
tium shows local and focal areas of tubular atrophy and
dilatation often filled with proteinaceous casts in lumina,
mononuclear cell infiltration, and, rarely, interstitial fi-
brosis. Abnormal glomeruli are frequently seen adjacent
to foci of tubulointerstitial lesions. Glomerular and tubu-
lointerstitial lesions were less pronounced in kidneys of
rats fed soy protein concentrate (Fig. 1B and E). By con-
trast, most of the glomeruli and tubules, and the surround-
ing interstitium are preserved in kidneys of animals fed
flaxseed meal (Fig. 1C and F).
The percentages of total abnormal glomeruli and with
mesangial expansion and with glomerular sclerosis are
summarized in Table 3. Of the three groups, rats fed
casein had the greatest number of abnormal glomeruli
with mesangial expansion (27.6% ± 3.7%) and sclerosis
(1.80% + 0.81%). Rats fed soy protein showed slightly
less number of abnormal glomeruli with mesangial ex-
pansion (24.4% ± 1.9%) and sclerosis (1.40% ± 0.79%)
than those fed casein but these differences were not sta-
tistically significant. Rats fed flaxseed meal, however,
showed the lowest percentage of abnormal glomeruli
with expanded mesangium (10.0% ± 2.3%) that were sig-
nificantly different from those fed casein or soy protein
concentrate (P < 0.01). Rats fed flaxseed meal also had
the lowest percentage of abnormal glomeruli with scle-
rosis (0.80% ± 0.55%) but this decrease did not reach
statistical significance.
The data for tubulointerstitial score from each ani-
mal fed the three different diets are shown in Table 4.
The Kruskal-Wallis nonparametric rank test show that
overall there is a significant difference among the three
diet groups with P = 0.03. There was a statistically lower
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Fig. 1. Representative light micrographs periodic acid-Schiff (PAS)-stained kidney sections from obese spontaneously hypertensive/NIH-corpulent
(SHR/N-cp) rats fed with either casein (A), soy protein concentrate (B), or flaxseed meal (C) (×40). (A) Some glomeruli show increased PAS
staining, whereas others are sclerotic. The tubulointerstitium shows foci of atrophic or dilated tubules, some filled with proteinaceous casts inside
lumina and surrounded by mononuclear cell infiltrate, and, rarely, interstitial fibrosis. (B) Glomerular and tubulointerstitial lesions appear to be less
prominent with soy protein concentrate feeding. (C) In contrast, glomerular and tubulointerstitial lesions are markedly reduced by flaxseed meal
supplementation. Higher magnification (×200) shows essentially similar pattern of severity of lesions with casein (D), soy protein concentrate (E),
or flaxseed meal (F).
TI score for flaxseed meal diet compared to casein diet
(P = 0.015). However, differences between soy protein
and casein and between flaxseed and soy protein were
not significant, with P = 0.48 and P = 0.08, respectively.
DISCUSSION
To our knowledge, the present study is the first to
demonstrate that substituting flaxseed meal for casein
in the diet significantly reduces urinary protein excre-
tion and renal glomerular and tubulointerstitial lesions
in obese SHR/N-cp rats with hyperglycemia and hyper-
insulinemia. Soy protein substitution also reduced pro-
teinuria and renal pathologic lesions in these animals but
these reductions were only minimal and did not reach
statistical significance. Flaxseed meal or soy protein sup-
plementation was not associated with significant changes
in plasma glucose levels in obese animals, indicating that
the observed renal protective effects of flaxseed meal or
soy protein were independent of glycemic control.
It should also be noted that, except for the protein
source, the diets used in the present study were similar in
the total amounts of protein, fat, carbohydrate, minerals,
sodium, and vitamins. In addition, there were no signifi-
cant differences between the food intake and final body
weights among the three diet groups. Moreover, urinary
urea excretion also did not differ significantly among the
three groups, which further suggests that the total amount
of protein intake of the animals was similar. Therefore, it
seems highly unlikely that the different effects of flaxseed
meal and soy protein on proteinuria and nephropathy can
be ascribed to differences in protein, energy or fat intake.
Several groups of investigators have shown a benefi-
cial renal effect of soy protein in other animal models
of chronic renal disease. Williams and Walls [6] were
the first to show that in rats with subtotal nephrectomy
substituting soybean for casein in the diet resulted in
less proteinuria, less hypertrophy of the remnant kid-
ney, less glomerular sclerosis and tubular atrophy, as well
as lower mortality. Iwasaki et al [10] also showed that
replacing dietary casein with soy protein isolate for 18
months or longer in the Fischer 344 (F344) rat, which de-
velop age-related chronic nephropathy, slowed the pro-
gression of renal pathologic lesions and improved their
survival. Other groups have shown similar benefits of soy
protein feeding in rodent models of inherited polycystic
kidney disease (PKD), namely, the DBA/2FG-pcy (pcy)
mouse [11], CDI-pcy/pcy mouse [12], and the Han:SPRD-
cy rat [13]. In all these PKD models, soy protein substi-
tution was found to be effective not only in slowing cyst
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Table 4. Tubulointerstitial score in obese spontaneously
hypertensive/NIH-corpulent (SHR/N-cp) rats fed a diet supplemented
with either casein, soy protein concentrate, and flaxseed meal
Tubulointerstitial scorea
Diet 0 1+ 2+ 3+ 4+
Number of rats Total
Casein 0 4 3 3 0 10
Soy protein 2 4 1 3 0 10
Flaxmeal 7 1 0 2 0 10
aGrading was based on semiquantitative analysis of the severity of tubuloint-
erstitial damage using a score of 0 to 4+.
growth but also in reducing noncystic pathologic lesions
in the tubules and the renal intertstitium. More recently,
Maddox et al [19] showed that feeding a diet containing
25% soy protein isolate as compared to casein-containing
diet was also effective in slowing the development of
proteinuria and glomerular injury in the obese Zucker
rat. In the present study, however, we found only mi-
nor and insignificant reductions in proteinuria and renal
lesions with soy protein replacement. Because soy pro-
tein feeding per se did not have any significant effect on
hyperglycemia and hyperinsulinemia, it is possible that
the persistence of the diabetic and insulin resistant state in
obese SHR/N-cp rats during the study might have limited
renal protective effects of soy protein ingestion. In one
clinical study of male patients with type II diabetes melli-
tus, obesity, hypertension, and proteinuria, consumption
of a soy-based diet (that provided soy protein as half of
the daily protein intake) for 8 weeks had no significant
effects on GFR, proteinuria, and glycohemoglobin levels
in these subjects [32].
Our results are complementary to previous reports by
other groups showing a renal protective effect of dietary
flaxseed in animals and humans with chronic renal dis-
ease. Hall et al [20] first reported a renal protective effect
of dietary flaxseed in the MRL/lpr mouse, a murine model
of lupus nephritis. These investigators found that feeding
15% flaxseed diet as opposed to a standard rodent diet
without flaxseed for 14 weeks in female MRL/lpr mice
delayed the onset of proteinuria and preserved GFR in
these animals. Subsequently, the same group of inves-
tigators applied dietary flaxseed to patients with lupus
nephritis and found that flaxseed supplementation given
sequentially at 4 weekly intervals in these patients re-
duced proteinuria and increased creatinine clearance in
proportion to increasing dose of flaxseed [23]. Similar
beneficial effects of dietary flaxseed have also been ob-
served in the rat 5/6 renal ablation model [21] and in
the Han:SPRD-cy rat model of PKD [22]. Our study
indicates that dietary flaxseed supplementation is also
protective against chronic renal disease in a model of obe-
sity and type II diabetes mellitus and that flaxseed meal
is more effective than soy protein in reducing protein-
uria and glomerular and tubulointerstitial lesions in this
model. Our data further show that this greater renal bene-
ficial effect of dietary flaxseed is independent of the quan-
tity of protein intake and the hyperglycemic state of the
animals. However, we observed that flaxseed meal sup-
plementation as compared to casein and soy protein
concentrate was associated with lower plasma insulin
levels in obese rats, suggesting an improvement of hyper-
insulinemia and insulin-resistance in these animals. Since
insulin itself is one of the hormonal factors implicated
in the pathogenesis of mesangial matrix accumulation in
diabetic nephropathy [33, 34], and since reduction of in-
sulin levels in vivo delays or reduces glomerulosclerosis
and tubular and interstitial lesions in obese hyperinsu-
linemic Zucker rats [35], it is possible that the reduction
of hyperisulinemia by flaxseed meal in the present study
may have contributed in part to the improvement of pro-
teinuria and renal lesions in obese SHR/N-cp rats. Taken
together, these studies and our present results indicate
that dietary flaxseed can be protective against renal in-
jury in various types of chronic renal disease suggesting
that this benefit extends to renal disease associated with
type II diabetes mellitus.
The present study did not determine which compo-
nent(s) in flaxseed meal is (are) responsible for its salu-
tary effects on proteinuria and nephropathy. Previous
studies showing a protective effect of dietary flaxseed on
the kidney have used either whole flaxseed or flaxseed oil.
Whole flaxseed contains approximately 41% fat and 21%
protein of the seed weight [36, 37]. The fat in the intact
seed is particularly rich in a-linolenic acid, which accounts
for approximately 57% of the total fatty acid in flaxseed
oil. Because a-linolenic acid has intrinsic lipid-lowering
and anti-inflammatory properties [38–42], and because
a-linolenic acid content was found to be increased in re-
nal tissues of subtotally nephrectomized rats fed flaxseed
and flax oil [21], this component of flaxseed has been
suggested to be partly responsible for the beneficial renal
effects of dietary flaxseed observed in earlier studies [20–
23]. However, the flaxseed meal used in our study, unlike
that in earlier studies, has been fully defatted and does
not contain a-linolenic acid. This excludes the possibility
that this fatty acid played a role in the reduction of pro-
teinuria and renal pathologic lesions afforded by flaxseed
meal in the present study and suggests that other compo-
nents of flaxseed may be involved. Which constituent(s)
of defatted flaxseed is (are) responsible for its renopro-
tective effect needs further investigation.
It is known that flaxseed is also the richest source of
lignans [43], which is one of the major classes of phytoe-
strogens, a group of plant-derived diphenolic compounds
structurally related to endogenous estrogen that possess
a wide range of biologic activities [44]. For example, plant
lignans have been shown to induce specific reversible and
competitive antagonism of platelet-activating factor
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(PAF), a major factor involved in inflammation [45]. Since
serum levels and urinary excretion of PAF are increased
in patients with systemic lupus erythematosus and in
mice with lupus nephritis [46, 47], inhibitory action of
flaxseed-derived lignans on PAF could conceivably ex-
plain the beneficial effects of dietary flaxseed in lupus
nephritis, as was suggested by Hall et al [20] in their stud-
ies of the MRL/lpr mouse. Lignans are also known to
possess antiproliferative properties [48, 49], which may
also contribute to the inhibitory effects of flaxseed on
glomerular or renal epithelial cell proliferation seen in
PKD and proliferative glomerular diseases. One of the
major lignan precursors derived from flaxseed, SDG, has
been shown to have antioxidant activity in animals [50–
52]. In addition, Clark et al have shown that chronic
oral administration of SDG (the lignan precursor also
extracted from flax) for 22 weeks in MRL/lpr mice de-
layed the onset of proteinuria and preserved GFR and
kidney weight in a time- and dose-dependent manner
[53]. This study further suggests that SDG in flaxseed
exerts renal protective effects similar to the whole
flaxseed in this mouse model of lupus nephritis. The
flaxseed meal used in the present study also contains very
high amounts of SDG (e.g., 17.0 mg/g). Thus, it is possible
that SDG may have contributed to the renal protective
effects of flaxseed meal observed in the present study.
Finally, it is also conceivable that the various cellular
actions of lignans may represent a mechanism associ-
ated with the protective effects of flaxseed in a variety of
chronic renal diseases, including diabetic nephropathy.
Whether each one or all of these putative biochemical
and cellular actions of lignans are involved in the renal
protection by flaxseed in vivo remains to be determined.
CONCLUSION
We have shown for the first time that dietary pro-
tein substitution with flaxseed meal reduces proteinuria
and glomerular and tubulointerstitial lesions in obese
SHR/N-cp rats. These initial studies indicate that flaxseed
meal is more effective than soy protein in reducing pro-
teinuria and renal histologic injury in this model and that
this beneficial effect is independent of the amount of pro-
tein intake and glycemic control. Which dietary compo-
nent(s) present in flaxseed meal or soy protein is (are)
responsible for the observed renal protective effect
remains to be determined. The marked reduction in pro-
teinuria and renal protective effects of flaxseed meal may
have important therapeutic implications in patients with
type II diabetes mellitus and diabetic nephropathy and,
therefore deserve further study in humans with these dis-
orders. Supplementation with flaxseed meal in the diet
may provide a novel therapeutic strategy to reduce pro-
teinuria and preserve renal function.
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